iCAD Inc, a provider of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer, announced that positive data using the Company’s Xoft Axxent Electronic Brachytherapy System to treat non-melanoma skin cancer (NMSC) were presented at ASTRO.

The data show that at three years post-treatment, patients who had high dose rate (HDR) electronic brachytherapy with the Xoft System had good cosmesis, low toxicity levels and no recurrences. The Xoft System is the only electronic brachytherapy system with peer reviewed published clinical data supporting its use in skin cancer. More than 2,000 NMSC patients have been successfully treated with the Xoft System.